StockWatch
·

Fabtech Technologies Cleanrooms Ltd Q2 FY27 Results

FABCLEANQ2 FY27 Results
Filing
FABTECH TECHNOLOGIES CLEANROOMS · Q2 FY27 · THE VERDICT

The 75% Quarter That Grew Faster Than Its Profit

Fabtech delivered record-breaking 75% revenue growth and a ₹468 Cr order book in H1 FY27, but PAT grew only 55% and margins stayed flat at 7.7%. The earnings call reveals why profitability lagged—and why the market repriced -34.7% from all-time highs.

06 Nov 2026 · 6 min read

Fabtech Technologies delivered the headline that markets might have craved—a ₹133 Cr quarter (75% revenue growth) and a record ₹468 Cr order book (2.3x since March). Yet the company's earnings call revealed an uncomfortable truth: profitability lagged volume dramatically. PAT grew only 55% despite 75% revenue expansion. EBITDA margin stayed flat at 7.7% despite scale. This is not the margin-expansion story of a business scaling elegantly; this is a business executing growth under margin pressure. The street noticed: FII exited completely to 0%, and the stock repriced -34.7% from its all-time high of ₹575 to ₹375.5 (as of Nov 5, 2026).

H1 Revenue

₹133 Cr

+75% YoY | Standalone ₹107 Cr (+41% YoY)

H1 PAT

₹5.15 Cr

+55% YoY | Growth lagged volume by 20 points

EBITDA Margin

7.7%

Flat vs prior H1 | Expected improvement didn't materialize

Order Book

₹468 Cr

2.3x vs Mar26 | But ~₹40 Cr gap to H1 execution

Where the gap came from

Revenue scaled 75%, but cost pressures and execution constraints throttled profit growth. Raw material inflation hit hard—aluminum prices jumped from ₹220 to ₹440 in just two months. Reference projects, like the Awaree Solar cleanroom build, were deliberately taken at lower margins to establish credentials with multinationals. And the Hyderabad facility was ramping, absorbing setup and absorption costs. Management stated: 'This year we were hit with geopolitical conflicts, broken supply chains, material costs swinging week to week. Never before has the metal market been so unpredictable.' The math is stark: 75% revenue growth absorbed by input inflation, reference-project margin sacrifice, and operating leverage headwinds meant PAT grew only 55%—a 20-point divergence between headline and profit growth.

The order book paradox: ₹468 Cr that didn't execute

Analysts immediately pressed on the order book mechanics. Opening ₹199 Cr + new orders ~₹517 Cr declared = ₹716 Cr supply, but closing book was ₹468 Cr. Where did ₹248 Cr go? The answer revealed the quarter's real story. Approximately ₹40 Cr was 'execution slippage'—orders that should have converted to H1 revenue didn't. Management disclosed: 'Customers are not ready to accept deliveries despite design finalization. Their buildings are still under construction.' Translation: the order book is stuffed with conditional orders—not firm sales awaiting production runs, but design-finalized orders held back by customer capex timing. H1 execution was ~₹130 Cr revenue on a ₹468 Cr book (28% conversion rate), revealing bottlenecks in either delivery capacity or customer acceptance readiness. This is not fraud, but it is a flag for order quality and execution constraints.

Management's key claims vs. what holds up

Revenue grew 75% in H1

₹133 Cr vs ~₹76 Cr prior H1 = 75% confirmed

Supported

PAT growth 55%+ in H1

₹5.15 Cr vs ~₹3.3 Cr prior H1 = ~55% confirmed

Supported

EBITDA margin 7.7%, maintained vs prior H1

₹10.28 Cr / ₹133 Cr = 7.7% correct, but flat not improved despite scale

Supported (but margin lagged expectations)

Order book doubled to ₹468 Cr

₹468 Cr at Sep-30 vs ~₹200 Cr in Mar = 2.3x growth (not 2x)

Slightly overstated

Margins to improve in H2

Management stated 'PAT in H2 to exceed H1 fairly substantially' but drivers unclear given geopolitical inflation pressure; contingent on order execution & new order mix

Overstated (proof pending)

What changed on this call

Internal guidance revised sharply upward—external guidance stayed cautious. Prior quarters guided to 20-30% FY27 growth. The H1 order book acceleration to ₹468 Cr (and actual 75% H1 revenue delivery) prompted management to internally reframe: now targeting 70-80% FY27 growth internally, but continuing to guide the market conservatively to 20-30% for H2. This gap between internal conviction and external communication is notable: management is signaling bull conviction internally while maintaining bear-case optionality externally. A hedging move that creates credibility questions.

Margin outlook flipped from implicit expansion to caution. Prior earnings hinted at margin improvement from scale. H1 delivered 7.7% EBITDA margin (flat vs prior year), prompting management to reset expectations downward: internally targeting 8-10% PAT margins, but externally stating 'same as H1 (7.7%) going forward.' The ambiguity created analyst frustration—internally optimistic, externally hedged. When management says both things simultaneously, neither is credible until proven.

Data center and semiconductor elevated as high-margin growth levers. Management pivoted strategic emphasis toward India Semiconductor Mission (12 approved fab projects) and data center cleanrooms (Kelvin partnership, ₹120 Cr pipeline). These verticals carry higher margins than legacy pharma and commoditized solar reference projects. Implication: FY27 margin recovery depends not just on input cost stabilization, but on a deliberate shift in order mix toward higher-margin verticals.

The working capital trap

Receivables of ₹129 Cr represent 97% of H1 revenue (₹133 Cr). For project-based businesses, milestone-linked collections are normal, but this ratio is tighter than most. Management tied collections to project milestones and promised improvement by Mar 2027. October collections started, but near-term cash flow remains compressed. The company is funding growth with working capital leverage: strong order book, tight cash conversion. As long as collections track management's timeline and new orders maintain momentum, this is sustainable. If collections slip or growth stalls, cash runway becomes constrained.

How the market is positioned

The stock repriced -34.7% from its all-time high of ₹575 to ₹375.5 (as of Nov 5, 2026). It sits below SMA20 (₹436.57) and SMA50 (₹453.27), though above SMA200 (₹357.09). RSI at 36.6 suggests neutral momentum, but volume is increasing—a sign of either capitulation or accumulation breaking hands.

Institutional flows have turned decisively negative. FII ownership dropped to 0% (from 0.69% in FY25 Q4), a complete exit. DII reduced from 8.97% (FY26 Q2) to 5.65% (FY26 Q4)—a 3.32 percentage point outflow. Only promoter ownership (68.49%) remains stable. The institutional pullback reflects caution on margin recovery and execution risk—exactly the tensions this quarter surfaced.

This repricing may be overcorrected. Fabtech is executing a bold strategy: ₹468 Cr order book, 75% H1 growth, ₹50k sqm Hyderabad facility now operational. Long-term ambition—₹1,000+ Cr revenue by 2030, 25-30% market share by FY30—is credible given the cleanroom market is growing 50-70% annually. But the near-term margin recovery is unproven, the order book quality is conditional, and working capital is tight. At ₹375.5, the market is pricing in execution failure on all three fronts. If management delivers H2 milestone collections, order book conversion, and even flat margins into FY28, the risk/reward tilts favorable. Until then, caution is warranted.

The bull-bear ledger

  • Order book 2.3x in 6 months; largest in company history (₹468 Cr)

  • Revenue growth 75% outpaced guidance by 2.5x; demonstrates execution capability

  • Cleanroom market growing 50-70% annually; Fabtech targeting 25-30% market share by FY30

  • Data center (Kelvin ₹120 Cr pipeline) & semiconductor (India Semiconductor Mission) add high-margin growth levers

  • Hyderabad 50k sqm facility operational; automation-enabled manufacturing ready for scale

  • PAT growth (55%) significantly lagged revenue growth (75%); profitability didn't scale

  • EBITDA margin flat at 7.7% despite 75% growth; expected improvement didn't materialize

  • Order-to-execution gap of ~₹40 Cr reveals orders are conditional, not firm sales

  • Working capital burden: ₹129 Cr receivables = 97% of H1 revenue; collection risk near-term

  • FII exited completely (0%); DII trimmed 3.32pp; institutional sentiment turned negative

  • Margin guidance ambiguous: internally 8-10% target, externally 'same as H1' (7.7%)

  • Competition from Japanese (Daikin, ₹1,300 Cr revenue) and emerging European players intensifying

Risks, ranked by how much they should concern a holder

Margin compression may persist into FY28

High

H1 margins flat at 7.7% despite 75% growth; PAT grew only 55% of revenue growth rate. If reference projects drag longer or input inflation persists, FY27/28 profitability growth will remain capped well below revenue growth, destroying valuation upside.

Order book quality contingent on customer building readiness

High

₹468 Cr order book, but ~₹40 Cr slippage vs H1 execution revealed orders are conditional. If customer capex cycles slow or construction delays accumulate, order-to-revenue conversion may miss H2 targets. FY27 guidance (70-80% internal) depends on executing this book.

Working capital may not improve by Mar 2027 as promised

Medium

₹129 Cr receivables (97% of H1 revenue) tied to milestone-linked collections. If reference projects slip, collection timeline extends. Cash flow tightens, limiting capacity to fund H2 growth or fund capex. Capex for expansion remains unquantified.

Competitive entry from Japanese/European players accelerates

Medium

Daikin (₹1,300 Cr annual revenue) and emerging European entrants see the same 50-70% cleanroom market growth that excites Fabtech. Intense competition on price/terms could accelerate margin compression in new orders, offsetting mix improvement.

Geopolitical supply chain volatility persists

Medium

Aluminum prices swung 100% in 2 months (₹220→₹440). If geopolitical tensions continue, input cost volatility remains unpredictable. Management hedging through customer contracts is reactive, not proactive. Risk of surprise margin hits persists.

Capex requirements unquantified; may require external financing

Low-Medium

Management stated capex 'under discussion' and banks have 'enhanced credit lines' but no guidance given. Growth target of 70-80% FY27 + ambition to reach ₹1,000+ Cr by 2030 requires significant capex. If cash generation disappoints, external equity dilution risk rises.

What to watch next

Concrete catalysts to resolve the debate:
  • 1 · H2 order book execution and revenue delivery (₹200+ Cr expected)

    The critical de-risker. If management delivers ₹200+ Cr H2 revenue from the ₹468 Cr order book, it proves order quality and manufacturing capacity are improving. Confirms 70-80% FY27 growth is achievable.

  • 2 · Milestone-linked receivables collections by Mar 2027

    Management promised collections would improve as reference projects complete. If receivables fall below 80% of quarterly revenue by Mar, working capital normalization is confirmed, freeing cash for capex.

  • 3 · H2 EBITDA margin trend—improvement or further compression?

    The real profitability test. If H2 EBITDA margin improves to 8%+ (vs H1 7.7%), it validates management's margin recovery narrative. If flat or lower, the margin headwind story persists into FY28.

The debate

The honest read: Fabtech is a long-term compounder executing a bold strategy in a genuinely growing market. Management is competent and honest about challenges (acknowledged execution constraints candidly on the call). But the quarter revealed a business growing faster than it's learning to profit—a classic scaling challenge. Near-term risks (margin recovery, working capital, order execution) are material. The bull case requires all three to resolve favorably by Mar 2027. The bear case requires any one to slip. At current valuations (-34.7% from ATH), the risk/reward is balanced, not skewed. This is a Hold until margin recovery is proven in H2/Mar 2027. The number to track is not revenue (secure), but H2 EBITDA margin—if it improves to 8%+ and receivables normalize, equity risk/reward tilts. Until then, caution.

Fabtech delivered a headline-grabbing quarter (75% revenue growth, ₹468 Cr order book) but profitability lagged dramatically (55% PAT growth, flat 7.7% margin). This is execution-at-scale risk masquerading as growth. The long-term opportunity is real: the cleanroom market is growing 50-70% annually, and Fabtech's target to capture 25-30% market share by 2030 is credible. But the near-term risks (margin recovery, working capital normalization, order execution) must resolve by Mar 2027 for valuations to recover. The stock's -34.7% drawdown from ATH may be overcorrection, but it's not yet a screaming buy. Watch H2 margin and collections—they're the keys to resolving the tension between headline growth and actual profitability.

Informational and educational content only. Not investment advice.